Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31279583 | 0.81 | KMT2A (0.42) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL440008 | 0.81 | KMT2A (0.42) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL810345 | 0.80 | KMT2A (0.69) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL7017942 | 0.80 | KMT2A (0.47) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL13735717 | 0.80 | TP53 (0.69) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL25595243 | 0.77 | CSNK1A1 (0.42) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL7020201 | 0.75 | KMT2A (0.44) | KMT2AMEN1L3MBTL1HTTALDH1A1 | |
| SCHEMBL20555434 | 0.73 | CSNK1A1 (0.50) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL9589836 | 0.72 | L3MBTL1 (0.43) | KMT2AGAAMEN1HSD17B10KDM4E | |
| SCHEMBL811552 | 0.71 | MBOAT4 (0.44) | KMT2AGAAMEN1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | KMT2A 1874/4885GAA 245/4885MEN1 1039/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | KMT2A 1823/4885GAA 248/4885MEN1 1029/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | KMT2A 1874/4885GAA 245/4885MEN1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.